Fusion Antibodies Plc (GB:FAB) has released an update.
Fusion Antibodies Plc, a Belfast-based CRO specializing in the development of antibodies for therapeutic drugs and diagnostics, announced the successful passing of all resolutions at its recent AGM. The company, established in 2001 and trading on AIM since December 2017, provides comprehensive antibody engineering and production services to an international clientele, including top global pharmaceutical companies. Fusion aims to expedite the drug development process through its advanced technological platforms amidst a rapidly growing monoclonal antibody therapeutics market.
For further insights into GB:FAB stock, check out TipRanks’ Stock Analysis page.
